Browse News
Filter News
Found 722,779 articles
-
Spruce Biosciences is developing what could be the first new therapy treating congenital adrenal hyperplasia (CAH) since the 1960s, and a new therapy for women with polycystic ovary syndrome.
-
GeNeuro is developing therapeutics that tackle the viral proteins that potentially contribute to neurodegeneration seen in patients with MS, amyotrophic lateral sclerosis (ALS) and even COVID-19.
-
In a Phase IIb study, data showed that Prota Therapeutics' oral immunotherapy led to 51% of children reaching clinical remission of their peanut allergy compared to placebo. See inside for this and more!
-
iSpecimen Presents New Research to Optimize Biobanking at International Society for Biological and Environmental Repositories 2022 Annual Meeting
5/19/2022
Company Gave Three Presentations, Including Oral Discussion on How New Technology Can Support the “Just-in-Time” Approach to Biobanking.
-
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
5/19/2022
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been granted an additional 180-day period from Nasdaq’s Listing Qualification Department, through November 14, 2022, to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
-
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)- FDA approval provides an important option for those unable to take oral formulation of TPOXX -
5/19/2022
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous (IV) formulation of TPOXX for the treatment of smallpox.
-
Inceptor Bio Announces $37 Million Series A Financing to Develop Cell Therapies for Difficult-to-Treat Cancers
5/19/2022
Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced the closing of a $37 million Series A financing led by Kineticos Ventures.
-
Nanox Announces Its First Quarter of 2022 Financial Results and Provides Business Update
5/19/2022
NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an innovative medical imaging technology company, today announced results for the first quarter ended March 31, 2022.
-
ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
5/19/2022
ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company’s Annual General Meeting on May 18, 2022.
-
Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric Cancer
5/19/2022
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to XMT-2056.
-
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
5/19/2022
Ocuphire Pharma, Inc. today announced positive topline results from the LYNX-1 Phase 3 pivotal clinical trial investigating its product candidate Nyxol® for night (or dim light) vision disturbances (NVD).
-
Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors
5/19/2022
Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a Phase 1 clinical trial in patients with advanced solid tumors where currently approved therapies have failed.
-
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
5/19/2022
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer.
-
Odyssey Therapeutics Appoints Industry Leader Jeffrey M. Leiden, M.D., Ph.D., as Board Chair
5/19/2022
Odyssey Therapeutics, Inc ., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced the appointment of industry veteran Jeffrey M. Leiden, M.D., Ph.D., as Chairman of the Board.
-
Schrödinger Announces Appointment of Arun Oberoi to Board of Directors
5/19/2022
Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022.
-
Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
5/19/2022
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing that DecisionDx-SCC can independently risk-stratify patients with cutaneous squamous cell carcinoma (SCC) and one or more risk factors according to their biologic risk of metastasis, consistent with findings in previous development and validation studies.
-
Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting
5/19/2022
Nimbus Therapeutics , a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, today announced the presentation of new data from multiple Phase 1 clinical studies of its investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor, NDI-034858, in both healthy volunteers and patients with moderate-to-severe psoriasis.
-
Alchemab Announces Publication of AntiBERTa, an Antibody-Specific Machine Learning Model with Multiple Applications
5/19/2022
Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, today announced the publication of research demonstrating the potential of AntiBERTa (Antibody-specific Bi-directional Encoder Representation and Transformers).
-
Teleflex Announces Regulatory Clearance for its UroLift® System in China for the Treatment of Benign Prostatic Hyperplasia (BPH)Will expand patient access to BPH treatment
5/19/2022
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it has received National Medical Products Administration (NMPA) approval for its UroLift ® System in China for treating benign prostatic hyperplasia (BPH).
-
Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
5/19/2022
Voyager Therapeutics, Inc. is scheduled to present new preclinical data on a family of AAV9-derived TRACER capsids demonstrating cross-species central nervous system transduction.